Subtype
Early Stage Breast Carcinoma
CI-CAN-00002563Explore in graph →
57 active trials2 approved drugs
- NCIt
- C94774
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002563Explore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07796880 | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT06902311 | Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)(H-ASSIST) | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors(PROFFi) | recruiting | Phase 2 | 164 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06970912 | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer(DNADalHR) | recruiting | Phase 2 | 393 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07366112 | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment(DNACDKHR) | recruiting | Phase 2 | 158 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04891068 | BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer(BRE-04) | recruiting | Phase 2 | 40 | University of Illinois at ChicagoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07071038 | Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients(SWIVEL) | recruiting | Phase 2 | 62 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05559164 | Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | recruiting | Phase 2 | 60 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | recruiting | Phase 2 | 88 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05332561 | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | recruiting | Phase 2 | 240 | German Cancer Research CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials